Scientists developed inhalable nanoparticles that carry rifampin, a common tuberculosis drug. The particles have a biodegradable core that holds the drug and a coating that helps them stick to lung immune cells called macrophages.
The particles go to the lungs and are taken up by macrophages where TB bacteria hide. The drug is released slowly so the lung keeps the medicine longer. Because of this, treatment might be needed once a week instead of every day.
Researchers tested the idea in two different mouse models and worked under BSL-3 safety rules. Next they will study combination therapy with other TB antibiotics.
Difficult words
- inhalable — able to be breathed into the lungs
- nanoparticle — a very small particle you cannot seenanoparticles
- biodegradable — able to break down naturally in the body
- macrophage — an immune cell that eats bacteria and debrismacrophages
- tuberculosis — a serious lung disease caused by bacteria
- rifampin — an antibiotic used to treat tuberculosis
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Do you prefer a weekly inhaled treatment or daily medicine? Why?
- Would you be worried about inhalable nanoparticles as a patient? Why or why not?
- Why do you think researchers worked under BSL-3 safety rules?
Related articles
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
Untreated Sleep Apnea Speeds Heart Aging and Raises Death Risk
A laboratory study using a long-term mouse model finds that untreated obstructive sleep apnea — recreated by repeated drops in oxygen during sleep — leads to faster cardiovascular aging and higher mortality. Researchers call for early screening and treatment.
